Release Date: 14-Feb-2023
Roche’s blockbuster Hemlibra has become the global standard of care for the treatment of Hemophilia A. The drug remains one of Roche's best-selling drugs and generated over a billion dollars in revenue once more in 2022. The company reported Hemlibra revenues of CHF 3.82 Billion (US$ 4.13 Billion) for the year 2022, a 27% increase over the CHF 3.02 Billion (US$ 3.26 Billion) recorded for 2021. With CHF 2.32 Billion (US$ 2.5 Billion) from the US alone accounting for 60% of drug sales in 2022, the US continued to be the largest contributor to regional sales. In addition, Japan became the drug's third-largest market in 2022 as a result of greater market penetration in the area. Roche is now conducting several late-stage clinical trials on different subgroups of Hemophilia A patients and results from these are expected to assist Hemlibra gain more approvals, broaden its patient base internationally, and have a beneficial impact on its sales.
Download Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028: